I appreciate the letter to the Editor from Yamazaki‐Nakashimada et al. concerning our report. First, we thank Yamazaki‐Nakashimada et al. for highlighting our mistake. Our report was not the first report on afebrile Kawasaki disease (KD). We would like to express our sincere apologies to Pediatrics International and its readers for this oversight.As Yamazaki‐Nakashimada et al. indicated, there were five previous articles on afebrile KD (Table ). Four of the five patients had coronary artery (CA) dilatations. Of these four patients, and our patients who had CA dilatation, four of the six were ≤7 months of age. Five of the six patients were male.Previous reports of afebrile Kawasaki diseasePatient ageSexCA dilatationTime to treatmentNo. clinical manifestationsBCG inoculation siteGeneral conditionCRP (mg/dL)/WBC (/μL)/Hb (mg/dL)/Plt (×104/μL)BT measurement methodDifferential diagnosisHinze et al.3 monthsM+2 weeks4 + rhinorrhea, irritabilityNAPoor feeding15.8/17 400/8.9/112AxillaryNAKato et al.2 yearsM+15 days2 + arthralgiaNANA4.1/11 500/NA/NANANAMaresi et al.2 monthsM+No treatment, deceased on 14th day2 + rhinorrhea, coughNA“Discreet”NA/15370/NA/47.6NANAPinches et al.3 monthsM+NA0NAGood1.6/21300/9.0/102NANAUlloa‐Gutierrez et al.5 yearsF–No treatment5NA“Acutely ill aspect”10.2/NA/NA/70.8NAASO, other infectious diseasesASO, anti‐streptolysin O antibody; BCG, bacillus Calmette–Guerin; BT, body temperature; CA, coronary artery; CRP, C‐reactive protein; Hb, hemoglobin; Plt, platelets; NA, not available; WBC, white blood cells.These five previous reports were in English, and were retrievable using PubMed. Although there were a few other articles on afebrile KD, they were not available on Pubmed or were not in
Pediatrics International – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud